Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 3 | 3 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 3 | 8 | 11 |
| 2004 | 4 | 2 | 6 |
| 2005 | 6 | 13 | 19 |
| 2006 | 3 | 7 | 10 |
| 2007 | 6 | 6 | 12 |
| 2008 | 5 | 6 | 11 |
| 2009 | 5 | 7 | 12 |
| 2010 | 5 | 10 | 15 |
| 2011 | 8 | 13 | 21 |
| 2012 | 6 | 5 | 11 |
| 2013 | 7 | 9 | 16 |
| 2014 | 16 | 14 | 30 |
| 2015 | 23 | 20 | 43 |
| 2016 | 13 | 18 | 31 |
| 2017 | 16 | 9 | 25 |
| 2018 | 17 | 19 | 36 |
| 2019 | 14 | 23 | 37 |
| 2020 | 17 | 21 | 38 |
| 2021 | 11 | 11 | 22 |
| 2022 | 0 | 10 | 10 |
| 2023 | 1 | 5 | 6 |
| 2024 | 8 | 11 | 19 |
| 2025 | 24 | 10 | 34 |
| 2026 | 12 | 6 | 18 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenstr?m macroglobulinemia. Blood. 2026 May 14; 147(20):2298-2314.
-
Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics. Am J Hematol. 2026 Jul; 101(7):1632-1649.
-
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clin Cancer Res. 2026 Apr 15; 32(8):1454-1461.
-
Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC. Sci Adv. 2026 Apr 03; 12(14):eaec8684.
-
Influence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC: Unraveling the Connection. Cancer Med. 2026 Apr; 15(4):e71738.
-
Loss of luminal lineage drives resistance to next-generation ERa antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer. Nat Commun. 2026 04 01; 17(1).
-
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes. Leukemia. 2026 May; 40(5):946-954.
-
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
-
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer. Nat Commun. 2026 Mar 12; 17(1).
-
Combination of Antidepressants and Chemotherapeutic Agents to Overcome P-Glycoprotein-Mediated Resistance in Cancer Patients: A Systematic Review. Med Sci (Basel). 2026 Mar 07; 14(1).